Utility of Serum Growth Arrest-Specific Protein 6 As a Biomarker of Severity and Prognosis After Severe Traumatic Brain Injury: A Prospective Observational Study

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2022 Jul 21

PMID 35859802

Authors

Bu-Kao Ni

Jian-Yong Cai

Xiao-Bo Wang

Qun Lin

Xue-Na Zhang

Jian-Hua Wu

Affiliations

Soon will be listed here.

Abstract

Objective: Growth arrest-specific protein 6 (Gas6) may harbor protective effects in acute brain injury. This study was designed to determine the relation of serum Gas6 levels to severity and prognosis after traumatic brain injury (TBI).

Methods: In this prospective cohort study of 114 controls and 114 patients with severe TBI, multivariate analysis was used to assess relationships between serum Gas6 levels, Glasgow coma scale (GCS) score, Rotterdam computed tomography (CT) score, postinjury 180-day mortality, overall survival and poor prognosis (Extended Glasgow outcome scale score 1-4).

Results: Significantly increased serum Gas6 levels of patients (median, 10.3 ng/mL versus 32.5 ng/mL; P < 0.001), as compared with controls, were independently correlated with Rotterdam CT score (t = 3.629, P < 0.001) and GCS score (t=-3.393, P = 0.001), and independently predicted 180-day mortality (odds ratio, 1.078; 95% confidence interval (CI), 1.007-1.154), overall survival (hazard ratio, 1.074; 95% CI, 1.012-1.139) and poor prognosis (odds ratio, 1.129; 95% CI, 1.059-1.205). Areas under receiver operating characteristic curve (AUCs) of serum Gas6 levels for discriminating risks of 180-day mortality and poor prognosis were 0.785 (95% CI, 0.699-0.857) and 0.793 (95% CI, 0.707-0.863), respectively; and serum Gas6 levels above 30.9 ng/mL and 28.3 ng/mL predicted 180-day mortality and poor prognosis with maximum Youden indices of 0.451 and 0.468, respectively. The predictive ability of serum Gas6 levels for mortality was similar to those of GCS score (AUC, 0.833; 95% CI, 0.751-0.896; P = 0.286) and Rotterdam CT score (AUC, 0.823; 95% CI, 0.740-0.888; P = 0.432). The discriminatory capability of serum Gas6 levels for the risk of poor prognosis was in the range of GCS score (AUC, 0.846; 95% CI, 0.766-0.906; P = 0.178) and Rotterdam CT score (AUC, 0.831; 95% CI, 0.750-0.895; P = 0.368).

Conclusion: Serum Gas6 may appear as a promising biochemical parameter for aiding in the assessment of trauma severity and prediction of prognosis among patients with severe TBI.

Citing Articles

Utility of serum chemokine-like factor 1 as a biomarker of severity and prognosis after severe traumatic brain injury: A prospective observational study.

Wu X, Su C, Tian D, Ye Y, Du Q, Chen J Brain Behav. 2024; 14(5):e3522.

PMID: 38773776 PMC: 11109498. DOI: 10.1002/brb3.3522.

References

Akalu Y, Rothlin C, Ghosh S . TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. Immunol Rev. 2017; 276(1):165-177. PMC: 5381815. DOI: 10.1111/imr.12522. View

Stein D, Hu P, Brenner M, Sheth K, Liu K, Xiong W . Brief episodes of intracranial hypertension and cerebral hypoperfusion are associated with poor functional outcome after severe traumatic brain injury. J Trauma. 2011; 71(2):364-73. DOI: 10.1097/TA.0b013e31822820da. View

Nik A, Sheikh Andalibi M, Ehsaei M, Zarifian A, Karimiani E, Bahadoorkhan G . The Efficacy of Glasgow Coma Scale (GCS) Score and Acute Physiology and Chronic Health Evaluation (APACHE) II for Predicting Hospital Mortality of ICU Patients with Acute Traumatic Brain Injury. Bull Emerg Trauma. 2018; 6(2):141-145. PMC: 5928271. DOI: 10.29252/beat-060208. View

Prieto A, Weber J, Tracy S, Heeb M, Lai C . Gas6, a ligand for the receptor protein-tyrosine kinase Tyro-3, is widely expressed in the central nervous system. Brain Res. 1999; 816(2):646-61. DOI: 10.1016/s0006-8993(98)01159-7. View

Rothlin C, Carrera-Silva E, Bosurgi L, Ghosh S . TAM receptor signaling in immune homeostasis. Annu Rev Immunol. 2015; 33:355-91. PMC: 4491918. DOI: 10.1146/annurev-immunol-032414-112103. View

Nagata K, Ohashi K, Nakano T, Arita H, Zong C, Hanafusa H . Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem. 1996; 271(47):30022-7. DOI: 10.1074/jbc.271.47.30022. View

In-Suk Bae M, Hyoung-Joon Chun M, Hyeong-Joong Yi M, Kyu-Sun Choi M . Using components of the Glasgow coma scale and Rotterdam CT scores for mortality risk stratification in adult patients with traumatic brain injury: A preliminary study. Clin Neurol Neurosurg. 2019; 188:105599. DOI: 10.1016/j.clineuro.2019.105599. View

Davanzo J, Sieg E, Timmons S . Management of Traumatic Brain Injury. Surg Clin North Am. 2017; 97(6):1237-1253. DOI: 10.1016/j.suc.2017.08.001. View

Khellaf A, Khan D, Helmy A . Recent advances in traumatic brain injury. J Neurol. 2019; 266(11):2878-2889. PMC: 6803592. DOI: 10.1007/s00415-019-09541-4. View

10.

Reith F, Lingsma H, Gabbe B, Lecky F, Roberts I, Maas A . Differential effects of the Glasgow Coma Scale Score and its Components: An analysis of 54,069 patients with traumatic brain injury. Injury. 2017; 48(9):1932-1943. DOI: 10.1016/j.injury.2017.05.038. View

11.

Pierce A, Keating A . TAM receptor tyrosine kinases: expression, disease and oncogenesis in the central nervous system. Brain Res. 2013; 1542:206-20. PMC: 4141466. DOI: 10.1016/j.brainres.2013.10.049. View

12.

Munakomi S . A comparative study between Marshall and Rotterdam CT scores in predicting early deaths in patients with traumatic brain injury in a major tertiary care hospital in Nepal. Chin J Traumatol. 2016; 19(1):25-7. PMC: 4897827. DOI: 10.1016/j.cjtee.2015.12.005. View

13.

Caldentey G, Garcia de Frutos P, Cristobal H, Garabito M, Berruezo A, Bosch X . Serum levels of Growth Arrest-Specific 6 protein and soluble AXL in patients with ST-segment elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2017; 8(8):708-716. DOI: 10.1177/2048872617740833. View

14.

Sainaghi P, Bellan M, Lombino F, Alciato F, Carecchio M, Galimberti D . Growth Arrest Specific 6 Concentration is Increased in the Cerebrospinal Fluid of Patients with Alzheimer's Disease. J Alzheimers Dis. 2016; 55(1):59-65. DOI: 10.3233/JAD-160599. View

15.

Wang K, Yang Z, Zhu T, Shi Y, Rubenstein R, Tyndall J . An update on diagnostic and prognostic biomarkers for traumatic brain injury. Expert Rev Mol Diagn. 2018; 18(2):165-180. PMC: 6359936. DOI: 10.1080/14737159.2018.1428089. View

16.

Xiao H, Chen J, Duan L, Li S . Role of emerging vitamin K‑dependent proteins: Growth arrest‑specific protein 6, Gla‑rich protein and periostin (Review). Int J Mol Med. 2021; 47(3). PMC: 7834955. DOI: 10.3892/ijmm.2020.4835. View

17.

Funakoshi H, Yonemasu T, Nakano T, Matumoto K, Nakamura T . Identification of Gas6, a putative ligand for Sky and Axl receptor tyrosine kinases, as a novel neurotrophic factor for hippocampal neurons. J Neurosci Res. 2002; 68(2):150-60. DOI: 10.1002/jnr.10211. View

18.

Burstyn-Cohen T, Maimon A . TAM receptors, Phosphatidylserine, inflammation, and Cancer. Cell Commun Signal. 2019; 17(1):156. PMC: 6881992. DOI: 10.1186/s12964-019-0461-0. View

19.

Morales A, Rojo Rello S, Cristobal H, Fiz-Lopez A, Arribas E, Mari M . Growth Arrest-Specific Factor 6 (GAS6) Is Increased in COVID-19 Patients and Predicts Clinical Outcome. Biomedicines. 2021; 9(4). PMC: 8065652. DOI: 10.3390/biomedicines9040335. View

20.

Guo Z, Liu J, Chang J, Zhang P, Jin H, Sun X . GAS6/Axl Signaling Modulates Blood-Brain Barrier Function Following Intravenous Thrombolysis in Acute Ischemic Stroke. Front Immunol. 2021; 12:742359. PMC: 8558492. DOI: 10.3389/fimmu.2021.742359. View